TargetRAF proto-oncogene serine/threonine-protein kinase [Y340E,Y341E](Homo sapiens (Human))
Novartis
US Patent
Novartis
US Patent
Affinity DataIC50: 0.00100nMAssay Description:The activity of a compound according to the present invention can be assessed by well-known in vitro & in vivo methods. Raf inhibition data provided ...More data for this Ligand-Target Pair
TargetRAF proto-oncogene serine/threonine-protein kinase [Y340E,Y341E](Homo sapiens (Human))
Novartis
US Patent
Novartis
US Patent
Affinity DataIC50: 0.00200nMAssay Description:The activity of a compound according to the present invention can be assessed by well-known in vitro & in vivo methods. Raf inhibition data provided ...More data for this Ligand-Target Pair
TargetRAF proto-oncogene serine/threonine-protein kinase [Y340E,Y341E](Homo sapiens (Human))
Novartis
US Patent
Novartis
US Patent
Affinity DataIC50: <0.00200nMAssay Description:The activity of a compound according to the present invention can be assessed by well-known in vitro & in vivo methods. Raf inhibition data provided ...More data for this Ligand-Target Pair
TargetRAF proto-oncogene serine/threonine-protein kinase [Y340E,Y341E](Homo sapiens (Human))
Novartis
US Patent
Novartis
US Patent
Affinity DataIC50: 0.00200nMAssay Description:The activity of a compound according to the present invention can be assessed by well-known in vitro & in vivo methods. Raf inhibition data provided ...More data for this Ligand-Target Pair
TargetRAF proto-oncogene serine/threonine-protein kinase [Y340E,Y341E](Homo sapiens (Human))
Novartis
US Patent
Novartis
US Patent
Affinity DataIC50: 0.00200nMAssay Description:The activity of a compound according to the present invention can be assessed by well-known in vitro & in vivo methods. Raf inhibition data provided ...More data for this Ligand-Target Pair
TargetRAF proto-oncogene serine/threonine-protein kinase [Y340E,Y341E](Homo sapiens (Human))
Novartis
US Patent
Novartis
US Patent
Affinity DataIC50: <0.00200nMAssay Description:The activity of a compound according to the present invention can be assessed by well-known in vitro & in vivo methods. Raf inhibition data provided ...More data for this Ligand-Target Pair
TargetRAF proto-oncogene serine/threonine-protein kinase [Y340E,Y341E](Homo sapiens (Human))
Novartis
US Patent
Novartis
US Patent
Affinity DataIC50: <0.00200nMAssay Description:The activity of a compound according to the present invention can be assessed by well-known in vitro & in vivo methods. Raf inhibition data provided ...More data for this Ligand-Target Pair
TargetRAF proto-oncogene serine/threonine-protein kinase [Y340E,Y341E](Homo sapiens (Human))
Novartis
US Patent
Novartis
US Patent
Affinity DataIC50: 0.00300nMAssay Description:The activity of a compound according to the present invention can be assessed by well-known in vitro & in vivo methods. Raf inhibition data provided ...More data for this Ligand-Target Pair
TargetRAF proto-oncogene serine/threonine-protein kinase [Y340E,Y341E](Homo sapiens (Human))
Novartis
US Patent
Novartis
US Patent
Affinity DataIC50: 0.00400nMAssay Description:The activity of a compound according to the present invention can be assessed by well-known in vitro & in vivo methods. Raf inhibition data provided ...More data for this Ligand-Target Pair
Affinity DataIC50: 0.00431nMpH: 7.5Assay Description:Compound potency against activated ERK2 was determined using a kinase assay that measures ERK2-catalyzed phosphorylation of biotinylated ERKtide pept...More data for this Ligand-Target Pair
TargetRAF proto-oncogene serine/threonine-protein kinase [Y340E,Y341E](Homo sapiens (Human))
Novartis
US Patent
Novartis
US Patent
Affinity DataIC50: 0.00500nMAssay Description:The activity of a compound according to the present invention can be assessed by well-known in vitro & in vivo methods. Raf inhibition data provided ...More data for this Ligand-Target Pair
TargetRAF proto-oncogene serine/threonine-protein kinase [Y340E,Y341E](Homo sapiens (Human))
Novartis
US Patent
Novartis
US Patent
Affinity DataIC50: 0.00500nMAssay Description:The activity of a compound according to the present invention can be assessed by well-known in vitro & in vivo methods. Raf inhibition data provided ...More data for this Ligand-Target Pair
TargetRAF proto-oncogene serine/threonine-protein kinase [Y340E,Y341E](Homo sapiens (Human))
Novartis
US Patent
Novartis
US Patent
Affinity DataIC50: 0.00500nMAssay Description:The activity of a compound according to the present invention can be assessed by well-known in vitro & in vivo methods. Raf inhibition data provided ...More data for this Ligand-Target Pair
TargetRAF proto-oncogene serine/threonine-protein kinase [Y340E,Y341E](Homo sapiens (Human))
Novartis
US Patent
Novartis
US Patent
Affinity DataIC50: 0.00500nMAssay Description:The activity of a compound according to the present invention can be assessed by well-known in vitro & in vivo methods. Raf inhibition data provided ...More data for this Ligand-Target Pair
TargetRAF proto-oncogene serine/threonine-protein kinase [Y340E,Y341E](Homo sapiens (Human))
Novartis
US Patent
Novartis
US Patent
Affinity DataIC50: 0.00500nMAssay Description:The activity of a compound according to the present invention can be assessed by well-known in vitro & in vivo methods. Raf inhibition data provided ...More data for this Ligand-Target Pair
TargetRAF proto-oncogene serine/threonine-protein kinase [Y340E,Y341E](Homo sapiens (Human))
Novartis
US Patent
Novartis
US Patent
Affinity DataIC50: 0.00500nMAssay Description:The activity of a compound according to the present invention can be assessed by well-known in vitro & in vivo methods. Raf inhibition data provided ...More data for this Ligand-Target Pair
TargetRAF proto-oncogene serine/threonine-protein kinase [Y340E,Y341E](Homo sapiens (Human))
Novartis
US Patent
Novartis
US Patent
Affinity DataIC50: 0.00500nMAssay Description:The activity of a compound according to the present invention can be assessed by well-known in vitro & in vivo methods. Raf inhibition data provided ...More data for this Ligand-Target Pair
Affinity DataIC50: 0.00500nMpH: 7.5Assay Description:Compound potency against activated ERK2 was determined using a kinase assay that measures ERK2-catalyzed phosphorylation of biotinylated ERKtide pept...More data for this Ligand-Target Pair
Affinity DataIC50: 0.00550nMpH: 7.5Assay Description:Compound potency against activated ERK2 was determined using a kinase assay that measures ERK2-catalyzed phosphorylation of biotinylated ERKtide pept...More data for this Ligand-Target Pair
TargetRAF proto-oncogene serine/threonine-protein kinase [Y340E,Y341E](Homo sapiens (Human))
Novartis
US Patent
Novartis
US Patent
Affinity DataIC50: 0.00600nMAssay Description:The activity of a compound according to the present invention can be assessed by well-known in vitro & in vivo methods. Raf inhibition data provided ...More data for this Ligand-Target Pair
TargetRAF proto-oncogene serine/threonine-protein kinase [Y340E,Y341E](Homo sapiens (Human))
Novartis
US Patent
Novartis
US Patent
Affinity DataIC50: 0.00600nMAssay Description:The activity of a compound according to the present invention can be assessed by well-known in vitro & in vivo methods. Raf inhibition data provided ...More data for this Ligand-Target Pair
TargetRAF proto-oncogene serine/threonine-protein kinase [Y340E,Y341E](Homo sapiens (Human))
Novartis
US Patent
Novartis
US Patent
Affinity DataIC50: 0.00600nMAssay Description:The activity of a compound according to the present invention can be assessed by well-known in vitro & in vivo methods. Raf inhibition data provided ...More data for this Ligand-Target Pair
TargetRAF proto-oncogene serine/threonine-protein kinase [Y340E,Y341E](Homo sapiens (Human))
Novartis
US Patent
Novartis
US Patent
Affinity DataIC50: 0.00600nMAssay Description:The activity of a compound according to the present invention can be assessed by well-known in vitro & in vivo methods. Raf inhibition data provided ...More data for this Ligand-Target Pair
Affinity DataIC50: 0.00612nMpH: 7.5Assay Description:Compound potency against activated ERK2 was determined using a kinase assay that measures ERK2-catalyzed phosphorylation of biotinylated ERKtide pept...More data for this Ligand-Target Pair
Affinity DataIC50: 0.00665nMpH: 7.5Assay Description:Compound potency against activated ERK2 was determined using a kinase assay that measures ERK2-catalyzed phosphorylation of biotinylated ERKtide pept...More data for this Ligand-Target Pair
Affinity DataIC50: 0.00671nMpH: 7.5Assay Description:Compound potency against activated ERK2 was determined using a kinase assay that measures ERK2-catalyzed phosphorylation of biotinylated ERKtide pept...More data for this Ligand-Target Pair
TargetRAF proto-oncogene serine/threonine-protein kinase [Y340E,Y341E](Homo sapiens (Human))
Novartis
US Patent
Novartis
US Patent
Affinity DataIC50: 0.00700nMAssay Description:The activity of a compound according to the present invention can be assessed by well-known in vitro & in vivo methods. Raf inhibition data provided ...More data for this Ligand-Target Pair
TargetRAF proto-oncogene serine/threonine-protein kinase [Y340E,Y341E](Homo sapiens (Human))
Novartis
US Patent
Novartis
US Patent
Affinity DataIC50: 0.00700nMAssay Description:The activity of a compound according to the present invention can be assessed by well-known in vitro & in vivo methods. Raf inhibition data provided ...More data for this Ligand-Target Pair
TargetRAF proto-oncogene serine/threonine-protein kinase [Y340E,Y341E](Homo sapiens (Human))
Novartis
US Patent
Novartis
US Patent
Affinity DataIC50: 0.00800nMAssay Description:The activity of a compound according to the present invention can be assessed by well-known in vitro & in vivo methods. Raf inhibition data provided ...More data for this Ligand-Target Pair
TargetRAF proto-oncogene serine/threonine-protein kinase [Y340E,Y341E](Homo sapiens (Human))
Novartis
US Patent
Novartis
US Patent
Affinity DataIC50: 0.00800nMAssay Description:The activity of a compound according to the present invention can be assessed by well-known in vitro & in vivo methods. Raf inhibition data provided ...More data for this Ligand-Target Pair
TargetRAF proto-oncogene serine/threonine-protein kinase [Y340E,Y341E](Homo sapiens (Human))
Novartis
US Patent
Novartis
US Patent
Affinity DataIC50: 0.00800nMAssay Description:The activity of a compound according to the present invention can be assessed by well-known in vitro & in vivo methods. Raf inhibition data provided ...More data for this Ligand-Target Pair
TargetRAF proto-oncogene serine/threonine-protein kinase [Y340E,Y341E](Homo sapiens (Human))
Novartis
US Patent
Novartis
US Patent
Affinity DataIC50: 0.00800nMAssay Description:The activity of a compound according to the present invention can be assessed by well-known in vitro & in vivo methods. Raf inhibition data provided ...More data for this Ligand-Target Pair
Affinity DataIC50: 0.00827nMpH: 7.5Assay Description:Compound potency against activated ERK2 was determined using a kinase assay that measures ERK2-catalyzed phosphorylation of biotinylated ERKtide pept...More data for this Ligand-Target Pair
Affinity DataIC50: 0.00837nMpH: 7.5Assay Description:Compound potency against activated ERK2 was determined using a kinase assay that measures ERK2-catalyzed phosphorylation of biotinylated ERKtide pept...More data for this Ligand-Target Pair
Affinity DataIC50: 0.00875nMpH: 7.5Assay Description:Compound potency against activated ERK2 was determined using a kinase assay that measures ERK2-catalyzed phosphorylation of biotinylated ERKtide pept...More data for this Ligand-Target Pair
Affinity DataIC50: 0.00900nMpH: 7.5Assay Description:Compound potency against activated ERK2 was determined using a kinase assay that measures ERK2-catalyzed phosphorylation of biotinylated ERKtide pept...More data for this Ligand-Target Pair
TargetRAF proto-oncogene serine/threonine-protein kinase [Y340E,Y341E](Homo sapiens (Human))
Novartis
US Patent
Novartis
US Patent
Affinity DataIC50: 0.00900nMAssay Description:The activity of a compound according to the present invention can be assessed by well-known in vitro & in vivo methods. Raf inhibition data provided ...More data for this Ligand-Target Pair
TargetRAF proto-oncogene serine/threonine-protein kinase [Y340E,Y341E](Homo sapiens (Human))
Novartis
US Patent
Novartis
US Patent
Affinity DataIC50: 0.00900nMAssay Description:The activity of a compound according to the present invention can be assessed by well-known in vitro & in vivo methods. Raf inhibition data provided ...More data for this Ligand-Target Pair
TargetRAF proto-oncogene serine/threonine-protein kinase [Y340E,Y341E](Homo sapiens (Human))
Novartis
US Patent
Novartis
US Patent
Affinity DataIC50: 0.00900nMAssay Description:The activity of a compound according to the present invention can be assessed by well-known in vitro & in vivo methods. Raf inhibition data provided ...More data for this Ligand-Target Pair
TargetRAF proto-oncogene serine/threonine-protein kinase [Y340E,Y341E](Homo sapiens (Human))
Novartis
US Patent
Novartis
US Patent
Affinity DataIC50: 0.00900nMAssay Description:The activity of a compound according to the present invention can be assessed by well-known in vitro & in vivo methods. Raf inhibition data provided ...More data for this Ligand-Target Pair
TargetRAF proto-oncogene serine/threonine-protein kinase [Y340E,Y341E](Homo sapiens (Human))
Novartis
US Patent
Novartis
US Patent
Affinity DataIC50: 0.00900nMAssay Description:The activity of a compound according to the present invention can be assessed by well-known in vitro & in vivo methods. Raf inhibition data provided ...More data for this Ligand-Target Pair
TargetRAF proto-oncogene serine/threonine-protein kinase [Y340E,Y341E](Homo sapiens (Human))
Novartis
US Patent
Novartis
US Patent
Affinity DataIC50: 0.00900nMAssay Description:The activity of a compound according to the present invention can be assessed by well-known in vitro & in vivo methods. Raf inhibition data provided ...More data for this Ligand-Target Pair
Affinity DataIC50: 0.00970nMpH: 7.5Assay Description:Compound potency against activated ERK2 was determined using a kinase assay that measures ERK2-catalyzed phosphorylation of biotinylated ERKtide pept...More data for this Ligand-Target Pair
Affinity DataIC50: 0.00977nMpH: 7.5Assay Description:Compound potency against activated ERK2 was determined using a kinase assay that measures ERK2-catalyzed phosphorylation of biotinylated ERKtide pept...More data for this Ligand-Target Pair
Affinity DataIC50: 0.0100nMpH: 7.5Assay Description:Compound potency against activated ERK2 was determined using a kinase assay that measures ERK2-catalyzed phosphorylation of biotinylated ERKtide pept...More data for this Ligand-Target Pair
TargetRAF proto-oncogene serine/threonine-protein kinase [Y340E,Y341E](Homo sapiens (Human))
Novartis
US Patent
Novartis
US Patent
Affinity DataIC50: 0.0100nMAssay Description:The activity of a compound according to the present invention can be assessed by well-known in vitro & in vivo methods. Raf inhibition data provided ...More data for this Ligand-Target Pair
TargetRAF proto-oncogene serine/threonine-protein kinase [Y340E,Y341E](Homo sapiens (Human))
Novartis
US Patent
Novartis
US Patent
Affinity DataIC50: 0.0100nMAssay Description:The activity of a compound according to the present invention can be assessed by well-known in vitro & in vivo methods. Raf inhibition data provided ...More data for this Ligand-Target Pair
TargetRAF proto-oncogene serine/threonine-protein kinase [Y340E,Y341E](Homo sapiens (Human))
Novartis
US Patent
Novartis
US Patent
Affinity DataIC50: 0.0100nMAssay Description:The activity of a compound according to the present invention can be assessed by well-known in vitro & in vivo methods. Raf inhibition data provided ...More data for this Ligand-Target Pair
TargetRAF proto-oncogene serine/threonine-protein kinase [Y340E,Y341E](Homo sapiens (Human))
Novartis
US Patent
Novartis
US Patent
Affinity DataIC50: 0.0100nMAssay Description:The activity of a compound according to the present invention can be assessed by well-known in vitro & in vivo methods. Raf inhibition data provided ...More data for this Ligand-Target Pair
Affinity DataIC50: 0.0100nMpH: 7.5Assay Description:Compound potency against activated ERK2 was determined using a kinase assay that measures ERK2-catalyzed phosphorylation of biotinylated ERKtide pept...More data for this Ligand-Target Pair